Name (Synonyms) | Correlation | |
---|---|---|
drug2852 | Telemedicine follow-up visit Wiki | 1.00 |
drug1400 | In-person in clinic follow-up visit Wiki | 1.00 |
drug880 | Diagnostic Laboratory Biomarker Analysis Wiki | 1.00 |
drug424 | Biospecimen Collection Wiki | 0.58 |
drug2312 | Questionnaire Administration Wiki | 0.38 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.08 |
D007239 | Infection NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This study investigates convalescent plasma (CCP) collected from the blood of patients who have recovered from COVID-19 before use in treating patients with current COVID-19 infection. "Convalescent plasma" means that the plasma is coming from someone who has recovered from a COVID-19 infection. There may be antibodies present in CCP, that targets SARS-CoV-2, the virus responsible for COVID-19. The purpose of this study is to learn more about COVID-19 convalescent plasma and the effect it may have in treating COVID-19 infection.
Description: Will be assayed for severe acute respiratory syndrome (SARS‐CoV‐2) immunoassay, coronavirus (CoV) PepSeq assay, and SARS‐CoV‐2 lenti‐based neutralizing antibody titer.
Measure: Convalescent plasma (CCP) units infused in coronavirus disease-2019 (COVID-19) patients Time: Up to 12 months after enrollmentDescription: Will naturally be compared to reported data from the other studies. Analysis will focus on demonstrating that the antibody content of donor plasma increases the odds of surviving past day 28. Will also develop a nomogram for the probability of success (alive at day 28), accounting for patient, donor material and donor antibody characteristics measurable covariates.
Measure: All-cause mortality Time: At day 28 post-CCP infusionDescription: Will be examined to see how this relates to the duration of hospitalization.
Measure: Donor antibody levels Time: Up to 28 days post-CCP infusionDescription: Will be assessed on a 7-point ordinal scale, as recommended by the WHO patient outcome R&D Blueprint Group.
Measure: Incidence of adverse events Time: Up to 28 days post-CCP infusionDescription: Will be assessed on a 7-point ordinal scale. The scale is as follows: Death; Hospitalized, on invasive mechanical ventilation or ECMO; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, requiring low flow supplemental oxygen; Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than per protocol RDV administration); Not hospitalized
Measure: CCP recipient outcomes Time: Up to 28 days post-CCP infusionDescription: Patient can stay at the hospital for up to 28 days post-CCP infusion
Measure: Duration of hospitalization (days) Time: Up to 28 days post-CCP infusionDescription: Will be assessed on a 7-point ordinal scale.
Measure: Time to clinical improvement (days) Time: Up to 28 days post-CCP infusion